Filgrastim

ATC CODE

  • L03AA02

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

  • Febrile neutropaenia.

NEMLC RECOMMENDATION

  • Approved under the following conditions:
    • Patients must have had 3 days of appropriate antimicrobial therapy without resolution of infection.
    • Filgrastim can be used up to a maximum of 5 days with a daily review of white cell count (WCC) . Failure to respond must prompt further investigation of neutropenia.

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 27 November 2008


INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • ARV -induced neutropenia.

NEMLC RECOMMENDATION

  • Not Approved
    This does not preclude the use of filgrastim in the management of febrile neutropenia (see above) in HIV infected patients.

REVIEW INDICATORS

  • RCTs , with improved clinically relevant outcomes, especially mortality

DATE RATIFIED

  • 27 November 2008


INDICATIONS AND NEMLC RECOMMENDATIONS 3

INDICATION

  • Prophylactic use in children with high-risk acute lymphoblastic leukaemia (HR-ALL) .

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • The emergence of evidence that routine use of GCSF improves outcomes in HR-ALL.
  • A significant reduction in the price of GCSF.

DATE RATIFIED

  • 3 December 2009


INDICATIONS AND NEMLC RECOMMENDATIONS 4

INDICATION

  • Peripheral blood stem cell harvesting in autologous stem cell harvesting in haematological malignancies.

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • n/a

DATE RATIFIED

  • 24 July 2014


INDICATIONS AND NEMLC RECOMMENDATIONS 5

INDICATION

  • Chemotherapy-induced febrile neutropenia.

NEMLC RECOMMENDATION

  • Approved
    for secondary prophylaxis in curable cancers requiring full dosing on-schedule, i.e. Hodgkins and germ cell tumours.

REVIEW INDICATORS

  • n/a

DATE RATIFIED

  • 9 February 2012


INDICATIONS AND NEMLC RECOMMENDATIONS 6

INDICATION

  • Chemotherapy-induced febrile neutropenia.

NEMLC RECOMMENDATION

  • Not Approved
    for primary prophylaxis as no overall survival benefit and limited mortality benefit has been shown.

REVIEW INDICATORS

  • n/a

DATE RATIFIED

  • 9 February 2012